Rabeprazole + Amoxicillin + Clarithromycin + Metronidazole

The combination of rabeprazole, amoxicillin, clarithromycin, and metronidazole (RACM) is a quadruple therapy regimen used for the eradication of Helicobacter pylori infection. This combination has been studied as a short-term, twice-daily treatment that provides excellent eradication rates with high compliance and few adverse effects. ## Therapeutic Use and Efficacy The RACM regimen has demonstrated superior efficacy compared to triple therapy combinations. In a randomized open, prospective single-center study, the RACM regimen administered for 5 days achieved an eradication rate of 94.5% by intention-to-treat analysis and 98.1% by per-protocol analysis, compared to 80.0% and 86.7% respectively for the triple therapy consisting of rabeprazole, amoxicillin, and clarithromycin (RAC). ## Dosage and Administration The RACM regimen typically consists of: - Rabeprazole: 10 mg twice daily - Amoxicillin: 750 mg twice daily - Clarithromycin: 200 mg twice daily - Metronidazole: 250 mg twice daily This combination is usually administered for a short duration of 5 days, which helps improve patient compliance while maintaining high efficacy. ## Mechanism of Action Each component in this quadruple therapy serves a specific purpose: 1. **Rabeprazole**: A proton pump inhibitor that decreases stomach acid production, creating a more favorable environment for antibiotics to work against H. pylori. 2. **Amoxicillin**: A beta-lactam antibiotic that inhibits bacterial cell wall synthesis. 3. **Clarithromycin**: A macrolide antibiotic that inhibits bacterial protein synthesis. 4. **Metronidazole**: A nitroimidazole antibiotic effective against anaerobic bacteria and certain parasites. It works by damaging bacterial DNA. The combination of clarithromycin and metronidazole is particularly effective because even though resistance to each individual antibiotic may be high, the prevalence of resistance to both drugs simultaneously is expected to be low. This means metronidazole can kill clarithromycin-resistant but metronidazole-susceptible strains, while clarithromycin can kill clarithromycin-susceptible but metronidazole-resistant strains. ## Advantages The RACM regimen offers several advantages: - High eradication rate (>94%) - Short treatment duration (5 days) - Simple twice-daily dosing - High compliance (98% reported) - Few serious adverse effects - Effective against strains with resistance to individual antibiotics This quadruple therapy represents an important treatment option for H. pylori infection, particularly in regions with high resistance to clarithromycin or metronidazole.

Other names

Rabeprazole-Amoxicillin-Clarithromycin-Metronidazole regimenQuadruple therapy